CLCM
FOLD

Crawford Lake Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Crawford Lake Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-80,000
Closed -$806K – 88
2017
Q2 		$806K Buy
+80,000
New +$644K 0.18% 98

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Crawford Lake Capital Management's FOLD Position: Q4 2017 in Review

Crawford Lake Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 34,635 shares — an estimated $522K sold.

Crawford Lake Capital Management first reported a position in FOLD in Q1 2017 and held it in 2 quarters. The position peaked at $522K in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

  • Crawford Lake Capital Management reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Crawford Lake Capital Management sold 34,635 Amicus Therapeutics shares in Q4 2017, an estimated $522K.
  • Crawford Lake Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 2 quarters.
  • Crawford Lake Capital Management's Amicus Therapeutics position peaked at $522K in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Crawford Lake Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.